Pharmacological Dose-Effect Profiles of Various Concentrations of Humanised Primary Bile Acid in Encapsulated Cells
Abstract
:1. Introduction
2. Materials and Methods
2.1. Microcapsule Production
2.2. Microscopy
2.3. Microencapsulated Cell Viability
2.4. Glucose-Induced Assessments of Microencapsulated Cells
2.5. Cytokine Assessments
2.6. Bioenergetic Assessments
2.7. Statistical Analysis
3. Results
3.1. Cell and CDCA Distribution
3.2. Cell Viability
3.3. Glucose-Induced Viability and Oxidative Stress
3.4. Insulin Release
3.5. Glycaemic-Induced Cytokine Production
3.6. Hyperglycaemic-Induced Cytokine Production
3.7. Bioenergetic Measurements
4. Discussion
4.1. Cell and CDCA Distribution and Cell Viability
4.2. Glucose-Induced Viability and Oxidative Stress
4.3. Glucose-Induced Insulin Release
4.4. Cytokine Biomarkers
4.5. Bioenergetic Measurements
5. Conclusions
Author Contributions
Funding
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Nurunnabi, M.; Khatun, Z.; Revuri, V.; Nafiujjaman, M.; Cha, S.; Cho, S.; Huh, K.M.; Lee, Y.-K. Design and strategies for bile acid mediated therapy and imaging. RSC Adv. 2016, 6, 73986–74002. [Google Scholar] [CrossRef]
- Lefebvre, P.; Cariou, B.; Lien, F.; Kuipers, F.; Staels, B. Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation. Physiol. Rev. 2009, 89, 147–191. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fiorucci, S.; Distrutti, E. Chenodeoxycholic Acid: An Update on Its Therapeutic Applications. Handb. Exp. Pharmacol. 2019, 256, 265–282. [Google Scholar] [CrossRef]
- Horikawa, T.; Oshima, T.; Li, M.; Kitayama, Y.; Eda, H.; Nakamura, K.; Tamura, A.; Ogawa, T.; Yamasaki, T.; Okugawa, T.; et al. Chenodeoxycholic Acid Releases Proinflammatory Cytokines from Small Intestinal Epithelial Cells Through the Farnesoid X Receptor. Digestion 2019, 100, 286–294. [Google Scholar] [CrossRef]
- Chen, X.; Yan, L.; Guo, Z.; Chen, Y.; Li, M.; Huang, C.; Chen, Z.; Meng, X. Chenodeoxycholic acid attenuates high-fat diet-induced obesity and hyperglycemia via the G protein-coupled bile acid receptor 1 and proliferator-activated receptor γ pathway. Exp. Ther. Med. 2017, 14, 5305–5312. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Z.; Shaha, R.; Jiang, K.; McBride, R.; Frick, C.; Oakey, J. Composite Hydrogels With Controlled Degradation in 3D Printed Scaffolds. IEEE Trans. Nanobiosci. 2019, 18, 261–264. [Google Scholar] [CrossRef] [PubMed]
- Ashimova, A.; Yegorov, S.; Negmetzhanov, B.; Hortelano, G. Cell Encapsulation Within Alginate Microcapsules: Immunological Challenges and Outlook. Front. Bioeng. Biotechnol. 2019, 7, 380. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ludwig, B.; Ludwig, S.; Steffen, A.; Knauf, Y.; Zimerman, B.; Heinke, S.; Lehmann, S.; Schubert, U.; Schmid, J.; Bleyer, M.; et al. Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes. Proc. Natl. Acad. Sci. USA 2017, 114, 11745–11750. [Google Scholar] [CrossRef] [Green Version]
- Opara, E.C.; Mirmalek-Sani, S.H.; Khanna, O.; Moya, M.L.; Brey, E.M. Design of a bioartificial pancreas(+). J. Investig. Med. 2010, 58, 831–837. [Google Scholar] [CrossRef] [Green Version]
- Ishihara, H.; Asano, T.; Tsukuda, K.; Katagiri, H.; Inukai, K.; Anai, M.; Kikuchi, M.; Yazaki, Y.; Miyazaki, J.I.; Oka, Y. Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia 1993, 36, 1139–1145. [Google Scholar] [CrossRef] [Green Version]
- Miyazaki, J.; Araki, K.; Yamato, E.; Ikegami, H.; Asano, T.; Shibasaki, Y.; Oka, Y.; Yamamura, K. Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: Special reference to expression of glucose transporter isoforms. Endocrinology 1990, 127, 126–132. [Google Scholar] [CrossRef] [PubMed]
- Davis, W.A.; Peters, K.E.; Makepeace, A.; Griffiths, S.; Bundell, C.; Grant, S.F.A.; Ellard, S.; Hattersley, A.T.; Paul Chubb, S.A.; Bruce, D.G.; et al. Prevalence of diabetes in Australia: Insights from the Fremantle Diabetes Study Phase II. Intern. Med. J. 2018, 48, 803–809. [Google Scholar] [CrossRef] [PubMed]
- Tsalamandris, S.; Antonopoulos, A.S.; Oikonomou, E.; Papamikroulis, G.A.; Vogiatzi, G.; Papaioannou, S.; Deftereos, S.; Tousoulis, D. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur. Cardiol. Rev. 2019, 14, 50–59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Asmat, U.; Abad, K.; Ismail, K. Diabetes mellitus and oxidative stress—A concise review. Saudi Pharm. J. 2015, 24, 547–553. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rehman, K.; Akash, M.S.H. Mechanism of Generation of Oxidative Stress and Pathophysiology of Type 2 Diabetes Mellitus: How Are They Interlinked? J. Cell. Biochem. 2017, 118, 3577–3585. [Google Scholar] [CrossRef]
- Mathavan, S.; Chen-Tan, N.; Arfuso, F.; Al-Salami, H. The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes. Artif. Cells Nanomed. Biotechnol. 2015, 44, 1508–1519. [Google Scholar] [CrossRef]
- Erickson, R.A.; Epsten, R.M., Jr. Oral chenodeoxycholic acid increases small intestinal permeability to lactulose in humans. Am. J. Gastroenterol. 1988, 83, 541–544. [Google Scholar]
- Houten, S.M.; Watanabe, M.; Auwerx, J. Endocrine functions of bile acids. EMBO J. 2006, 25, 1419–1425. [Google Scholar] [CrossRef]
- Yui, S.; Kanamoto, R.; Saeki, T. Biphasic regulation of cell death and survival by hydrophobic bile acids in HCT116 cells. Nutr. Cancer 2009, 61, 374–380. [Google Scholar] [CrossRef]
- Yan, Z.W.; Dong, J.; Qin, C.H.; Zhao, C.Y.; Miao, L.Y.; He, C.Y. Therapeutic Effect of Chenodeoxycholic Acid in an Experimental Rabbit Model of Osteoarthritis. Mediat. Inflamm. 2015, 2015, 780149. [Google Scholar] [CrossRef] [Green Version]
- Shaik, F.B.; Panati, K.; Narasimha, V.R.; Narala, V.R. Chenodeoxycholic acid attenuates ovalbumin-induced airway inflammation in murine model of asthma by inhibiting the TH2 cytokines. Biochem. Biophys. Res. Commun. 2015, 463, 600–605. [Google Scholar] [CrossRef] [PubMed]
- Mooranian, A.; Negrulj, R.; Mikov, M.; Golocorbin-Kon, S.; Arfuso, F.; Al-Salami, H. Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study. J. Microencapsul. 2015, 32, 589–597. [Google Scholar] [CrossRef]
- Ghidoni, I.; Chlapanidas, T.; Bucco, M.; Crovato, F.; Marazzi, M.; Vigo, D.; Torre, M.L.; Faustini, M. Alginate cell encapsulation: New advances in reproduction and cartilage regenerative medicine. Cytotechnology 2008, 58, 49–56. [Google Scholar] [CrossRef] [Green Version]
- Wagle, S.R.; Kovacevic, B.; Walker, D.; Ionescu, C.M.; Shah, U.; Stojanovic, G.; Kojic, S.; Mooranian, A.; Al-Salami, H. Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies. Expert Opin. Drug Deliv. 2020, 17, 1361–1376. [Google Scholar] [CrossRef]
- Mooranian, A.; Zamani, N.; Mikov, M.; Goločorbin-Kon, S.; Stojanovic, G.; Arfuso, F.; Kovacevic, B.; Al-Salami, H. A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds. Saudi Pharm. J. 2019, 28, 165–171. [Google Scholar] [CrossRef]
- Jones, M.; Walker, D.; Ionescu, C.M.; Kovacevic, B.; Wagle, S.R.; Mooranian, A.; Brown, D.; Al-Salami, H. Microencapsulation of Coenzyme Q10 and bile acids using ionic gelation vibrational jet flow technology for oral delivery. Ther. Deliv. 2020, 11, 791–805. [Google Scholar] [CrossRef] [PubMed]
- Darrabie, M.D.; Kendall, W.F., Jr.; Opara, E.C. Characteristics of Poly-L-Ornithine-coated alginate microcapsules. Biomaterials 2005, 26, 6846–6852. [Google Scholar] [CrossRef] [PubMed]
- Leung, A.; Lawrie, G.; Nielsen, L.K.; Trau, M. Synthesis and characterization of alginate/poly-L-ornithine/alginate microcapsules for local immunosuppression. J. Microencapsul. 2008, 25, 387–398. [Google Scholar] [CrossRef] [PubMed]
- Bodratti, A.M.; Alexandridis, P. Formulation of Poloxamers for Drug Delivery. J. Funct. Biomater. 2018, 9, 11. [Google Scholar] [CrossRef] [Green Version]
- Mooranian, A.; Zamani, N.; Mikov, M.; Goločorbin-Kon, S.; Stojanovic, G.; Arfuso, F.; Al-Salami, H. Stability and biological testing of taurine-conjugated bile acid antioxidant microcapsules for diabetes treatment. Ther. Deliv. 2019, 10, 99–106. [Google Scholar] [CrossRef]
- Mooranian, A.; Zamani, N.; Takechi, R.; Al-Sallami, H.; Mikov, M.; Goločorbin-Kon, S.; Kovacevic, B.; Arfuso, F.; Al-Salami, H. Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. Artif. Cells Nanomed. Biotechnol. 2018, 46, S748–S754. [Google Scholar] [CrossRef]
- Mooranian, A.; Negrulj, R.; Takechi, R.; Mamo, J.; Al-Sallami, H.; Al-Salami, H. The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: Potential hypoglycaemic and anti-inflammatory effects. Drug Deliv. Transl. Res. 2018, 8, 543–551. [Google Scholar] [CrossRef]
- Mooranian, A.; Negrulj, R.; Al-Salami, H. The Influence of Stabilized Deconjugated Ursodeoxycholic Acid on Polymer-Hydrogel System of Transplantable NIT-1 Cells. Pharm. Res. 2016, 33, 1182–1190. [Google Scholar] [CrossRef] [Green Version]
- Mooranian, A.; Jones, M.; Ionescu, C.M.; Walker, D.; Wagle, S.R.; Kovacevic, B.; Chester, J.; Foster, T.; Johnston, E.; Mikov, M.; et al. Advancements in Assessments of Bio-Tissue Engineering and Viable Cell Delivery Matrices Using Bile Acid-Based Pharmacological Biotechnologies. Nanomaterials 2021, 11, 1861. [Google Scholar] [CrossRef]
- Mooranian, A.; Negrulj, R.; Al-Salami, H.; Morahan, G.; Jamieson, E. Designing anti-diabetic β-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis. Biotechnol. Prog. 2016, 32, 501–509. [Google Scholar] [CrossRef]
- Mooranian, A.; Negrulj, R.; Al-Salami, H. Flow vibration-doubled concentric system coupled with low ratio amine to produce bile acid-macrocapsules of β-cells. Ther. Deliv. 2016, 7, 171–178. [Google Scholar] [CrossRef]
- Mooranian, A.; Zamani, N.; Mikov, M.; Goločorbin-Kon, S.; Stojanovic, G.; Arfuso, F.; Kovacevic, B.; Al-Salami, H. Bio micro-nano technologies of antioxidants optimised their pharmacological and cellular effects, ex vivo, in pancreatic β-cells. Nanotechnol. Sci. Appl. 2020, 13, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Wagle, S.R.; Kovacevic, B.; Ionescu, C.M.; Walker, D.; Jones, M.; Carey, L.; Takechi, R.; Mikov, M.; Mooranian, A.; Al-Salami, H. Pharmacological and Biological Study of Microencapsulated Probucol-Secondary Bile Acid in a Diseased Mouse Model. Pharmaceutics 2021, 13, 1223. [Google Scholar] [CrossRef]
- Mooranian, A.; Negrulj, R.; Takechi, R.; Jamieson, E.; Morahan, G.; Al-Salami, H. New Biotechnological Microencapsulating Methodology Utilizing Individualized Gradient-Screened Jet Laminar Flow Techniques for Pancreatic β-Cell Delivery: Bile Acids Support Cell Energy-Generating Mechanisms. Mol. Pharm. 2017, 14, 2711–2718. [Google Scholar] [CrossRef]
- Mooranian, A.; Negrulj, R.; Arfuso, F.; Al-Salami, H. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: Potential applications in diabetes: A characterization study. Off. J. Control. Release Soc. 2015, 5, 511–522. [Google Scholar] [CrossRef]
- Lopez-Mendez, T.B.; Santos-Vizcaino, E.; Pedraz, J.L.; Orive, G.; Hernandez, R.M. Cell microencapsulation technologies for sustained drug delivery: Latest advances in efficacy and biosafety. J. Control. Release 2021, 335, 619–636. [Google Scholar] [CrossRef]
- Mooranian, A.; Negrulj, R.; Al-Salami, H. Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine β-cell Survival and the Inflammatory Response. BioNanoScience 2016, 6, 103–109. [Google Scholar] [CrossRef]
- Mooranian, A.; Negrulj, R.; Arfuso, F.; Al-Salami, H. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line. Artif. Cell Nanomed. Biotechnol. 2015, 44, 1642–1653. [Google Scholar] [CrossRef] [Green Version]
- Noh, K.; Kim, Y.M.; Kim, Y.W.; Kim, S.G. Farnesoid X receptor activation by chenodeoxycholic acid induces detoxifying enzymes through AMP-activated protein kinase and extracellular signal-regulated kinase 1/2-mediated phosphorylation of CCAAT/enhancer binding protein β. Drug Metab. Dispos. 2011, 39, 1451–1459. [Google Scholar] [CrossRef] [Green Version]
- Gai, Z.; Chu, L.; Xu, Z.; Song, X.; Sun, D.; Kullak-Ublick, G.A. Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage. Sci. Rep. 2017, 7, 9815. [Google Scholar] [CrossRef]
- Ma, Q. Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 401–426. [Google Scholar] [CrossRef] [Green Version]
- Tan, K.P.; Yang, M.; Ito, S. Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stress. Mol. Pharmacol. 2007, 72, 1380–1390. [Google Scholar] [CrossRef] [Green Version]
- McGlone, E.R.; Malallah, K.; Bloom, S.; Tan, T. Oral chenodeoxycholic acid increases post-prandial anorectic gut hormone levels and increases indices of insulin sensitivity. In Proceedings of the Society for Endocrinology BES 2019, Brighton, UK, 11–13 November 2019. [Google Scholar]
- Shihabudeen, M.S.; Roy, D.; James, J.; Thirumurugan, K. Chenodeoxycholic acid, an endogenous FXR ligand alters adipokines and reverses insulin resistance. Mol. Cell. Endocrinol. 2015, 414, 19–28. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Lee, F.Y.; Barrera, G.; Lee, H.; Vales, C.; Gonzalez, F.J.; Willson, T.M.; Edwards, P.A. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. USA 2006, 103, 1006–1011. [Google Scholar] [CrossRef] [Green Version]
- Cipriani, S.; Mencarelli, A.; Palladino, G.; Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 2010, 51, 771–784. [Google Scholar] [CrossRef] [Green Version]
- Paredes Juárez, G.A.; Spasojevic, M.; Faas, M.M.; de Vos, P. Immunological and technical considerations in application of alginate-based microencapsulation systems. Front. Bioeng. Biotechnol. 2014, 2, 26. [Google Scholar] [CrossRef] [Green Version]
- Brand, M.D.; Nicholls, D.G. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011, 435, 297–312. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wagle, S.R.; Kovacevic, B.; Walker, D.; Ionescu, C.M.; Jones, M.; Stojanovic, G.; Kojic, S.; Mooranian, A.; Al-Salami, H. Pharmacological and advanced cell respiration effects, enhanced by toxic human-bile nano-pharmaceuticals of probucol cell-targeting formulations. Pharmaceutics 2020, 12, 708. [Google Scholar] [CrossRef]
- Koster, J.C.; Permutt, M.A.; Nichols, C.G. Diabetes and insulin secretion: The ATP-sensitive K+ channel (K ATP) connection. Diabetes 2005, 54, 3065–3072. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mooranian, A.; Jones, M.; Walker, D.; Ionescu, C.M.; Wagle, S.R.; Kovacevic, B.; Chester, J.; Foster, T.; Johnston, E.; Kuthubutheen, J.; et al. Pharmacological Dose-Effect Profiles of Various Concentrations of Humanised Primary Bile Acid in Encapsulated Cells. Nanomaterials 2022, 12, 647. https://doi.org/10.3390/nano12040647
Mooranian A, Jones M, Walker D, Ionescu CM, Wagle SR, Kovacevic B, Chester J, Foster T, Johnston E, Kuthubutheen J, et al. Pharmacological Dose-Effect Profiles of Various Concentrations of Humanised Primary Bile Acid in Encapsulated Cells. Nanomaterials. 2022; 12(4):647. https://doi.org/10.3390/nano12040647
Chicago/Turabian StyleMooranian, Armin, Melissa Jones, Daniel Walker, Corina Mihaela Ionescu, Susbin Raj Wagle, Bozica Kovacevic, Jacqueline Chester, Thomas Foster, Edan Johnston, Jafri Kuthubutheen, and et al. 2022. "Pharmacological Dose-Effect Profiles of Various Concentrations of Humanised Primary Bile Acid in Encapsulated Cells" Nanomaterials 12, no. 4: 647. https://doi.org/10.3390/nano12040647